Real-world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada.
PWID
cascade of care
hepatitis C
opioid agonist therapy
screening
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
22 Feb 2024
22 Feb 2024
Historique:
revised:
02
02
2024
received:
28
10
2023
accepted:
15
02
2024
medline:
22
2
2024
pubmed:
22
2
2024
entrez:
22
2
2024
Statut:
aheadofprint
Résumé
Widespread screening for hepatitis C virus (HCV) is necessary for Canada to meet its HCV elimination goals by 2030. People who currently or previously injected drugs are at high risk for HCV. Opioid agonist therapy (OAT, such as methadone and buprenorphine) has been shown to help stabilize the lives of people who are opioid-dependent. The distribution of OAT in North America typically requires daily, weekly, or monthly clinic visits and presents an opportunity for engagement, screening and treatment for those at high-risk of HCV. In this study, HCV screening was conducted by staff at OAT clinics in Ontario from 2016 to 2020 and those with chronic infections were treated on-site with direct-acting antivirals. Point-of-care or dried blood spot (DBS) testing was used for antibodies, DBS or serum for HCV RNA and serum for HCV RNA at SVR12 (sustained virological response). Clinics screened 1954 people (mean age 40 years ±12, 63% male). Forty-five percent were antibody positive, of whom 64% were HCV RNA+. Eighty percent of those RNA+ set an appointment in which 99% attended. Ninety-six percent started treatment with 87% completing treatment. Sixty-eight percent of people who completed treatment submitted a sample for SVR12 testing of which 97% achieved a virological cure. Results suggest that HCV screening and treatment at OAT clinics is feasible, effective and warrants expansion. Data suggest strong treatment adherence due to high rates of SVR12 comparable with other OAT-based HCV treatment programs. The lack of SVR12 sampling could be addressed by either on-site phlebotomy or incentivizing SVR12 sampling.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Viral Hepatitis Care Network (VIRCAN)
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Lourenço L, Kelly M, Tarasuk J, et al. The hepatitis C epidemic in Canada: an overview of recent trends in surveillance, injection drug use, harm reduction and treatment. Can Commun Dis Rep. 2021;47(12):561-570.
Kwong JC, Ratnasingham S, Campitelli MA, et al. The impact of infection on population health: results of the Ontario burden of infectious diseases study. PLoS One. 2012;7(9):e44103.
Wong W, Haines A, Zangneh H, Shah H. Can we afford not to screen and treat hepatitis C virus infection in Canada? Can Liver J. 2018;1(2):51-65.
Ontario Agency for Health Protection and Promotion (Public Health Ontario). Hepatitis C in Ontario, 2018: Surveillance Summary One Year after a Case Definition Update. Ontario; 2020.
Roy É, Haley N, Leclerc P, Cédras L, Boivin J-F. Drug injection among street youth: the first time. Addiction. 2002;97(8):1003-1009.
Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction. 2012;107(6):1057-1065.
Fortier E, Høj SB, Sylvestre MP, et al. Injecting frequency trajectories and hepatitis C virus acquisition: findings from a cohort of people who inject drugs in Montréal, Canada. Int J Drug Policy. 2021;96:103439.
Ontario Ministry of Health and Long-Term Care. Ontario Drug Benefit Formulary/Comparative Drug Index, Summary of Changes-February 2018. In: Drug Programs Policy and Strategy Branch Ontario Public Drug Programs, editor. Toronto, ON. 2018.
Shah H, Bilodeau M, Burak KW, et al. The management of chronic hepatitis C: 2018 guideline update from the Canadian association for the study of the liver. Can Med Assoc J. 2018;190(22):E677-E687.
Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ. Hepatitis C treatment as prevention: evidence, feasibility, and challenges. Lancet Gastroenterol Hepatol. 2016;1(4):317-327.
Marshall AD, Saeed S, Barrett L, et al. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open. 2016;4(4):E605-E614.
Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016;62(6):683-694.
Merrill JO, Rhodes LA, Deyo RA, Marlatt GA, Bradley KA. Mutual mistrust in the medical care of drug users: the keys to the "narc" cabinet. J Gen Intern Med. 2002;17(5):327-333.
Habib SE, Adorjany LV. Hepatitis C and injecting drug use: the realities of stigmatisation and discrimination. Health Educ J. 2003;62(3):256-265.
Lang K, Neil J, Wright J, Dell CA, Berenbaum S, El-Aneed A. Qualitative investigation of barriers to accessing care by people who inject drugs in Saskatoon, Canada: perspectives of service providers. Subst Abuse Treat Prev Policy. 2013;8:35.
Heath AJ, Kerr T, Ti L, et al. Healthcare avoidance by people who inject drugs in Bangkok, Thailand. J Public Health (Oxf). 2016;38(3):e301-e308.
Biancarelli DL, Biello KB, Childs E, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80-86.
Henderson S, Stacey CL, Dohan D. Social stigma and the dilemmas of providing care to substance users in a safety-net emergency department. J Health Care Poor Underserved. 2008;19(4):1336-1349.
Brener L, Von Hippel W, Kippax S, Preacher KJ. The role of physician and nurse attitudes in the health care of injecting drug users. Subst Use Misuse. 2010;45(7-8):1007-1018.
van Boekel LC, Brouwers EP, van Weeghel J, Garretsen HF. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1-2):23-35.
Wakeman SE, Rich JD. Barriers to post-acute care for patients on opioid agonist therapy; an example of systematic stigmatization of addiction. J Gen Intern Med. 2017;32(1):17-19.
Elliott L, Bennett AS, Wolfson-Stofko B. Life after opioid-involved overdose: survivor narratives and their implications for ER/ED interventions. Addiction. 2019;114(8):1379-1386.
Harris M, Rhodes T. Venous access and care: harnessing pragmatics in harm reduction for people who inject drugs. Addiction. 2012;107(6):1090-1096.
Day E, Hellard M, Treloar C, et al. Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework. Liver Int. 2019;39(1):20-30.
Muncan B, Walters SM, Ezell J, Ompad DC. "They look at us like junkies": influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):53.
Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662-668.
Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;2009(3):Cd002209.
Nolan S, Dias Lima V, Fairbairn N, et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction. 2014;109(12):2053-2059.
Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174(12):1974-1981.
Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Intern Med. 2018;169(3):137-145.
Novick DM, Kreek MJ. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction. 2008;103(6):905-918.
Handford C, Kahan M, Srivastava A, et al. Buprenorphine/Naloxone for Opioid Dependence: Clinical Practice Guideline. Centre for Addiction and Mental Health; 2012.
Dore GJ, Altice F, Litwin AH, et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165(9):625-634.
Grebely J, Dore GJ, Zeuzem S, et al. Efficacy and safety of sofosbuvir/Velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clin Infect Dis. 2016;63(11):1479-1481.
Akiyama MJ, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH. Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: a randomized controlled trial. Ann Intern Med. 2019;170(9):594-603.
Graf C, Mücke MM, Dultz G, et al. Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis. Clin Infect Dis. 2020;70(11):2355-2365.
Rosenthal ES, Silk R, Mathur P, et al. Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs. Clin Infect Dis. 2020;71(7):1715-1722.
Grebely J, Tran L, Degenhardt L, et al. Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: a systematic review and meta-analysis. Clin Infect Dis. 2021;73(1):e107-e118.
Murphy G, Farah B, Wong W, et al. CADTH Therapeutic Reviews. Direct-Acting Antiviral Agents for Chronic Hepatitis C Genotype 1. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health 2014.
Wong WW, Lee KM, Singh S, Wells G, Feld JJ, Krahn M. Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. CMAJ Open. 2017;5(1):E97-E108.
Scott N, Iser DM, Thompson AJ, Doyle JS, Hellard ME. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. J Gastroenterol Hepatol. 2016;31(4):872-882.
van Santen DK, de Vos AS, Matser A, et al. Cost-effectiveness of hepatitis C treatment for people who inject drugs and the impact of the type of epidemic; extrapolating from Amsterdam, the Netherlands. PLoS One. 2016;11(10):e0163488.
Barbosa C, Fraser H, Hoerger TJ, et al. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs. Addiction. 2019;114(12):2267-2278.
Gutkind S, Schackman BR, Morgan JR, et al. Cost-effectiveness of hepatitis C virus treatment models for people who inject drugs in opioid agonist treatment programs. Clin Infect Dis. 2020;70(7):1397-1405.
Tatar M, Keeshin SW, Mailliard M, Wilson FA. Cost-effectiveness of universal and targeted hepatitis C virus screening in the United States. JAMA Netw Open. 2020;3(9):e2015756.
Mafirakureva N, Stone J, Fraser H, et al. An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis. Addiction. 2022;117(2):411-424.
Mason K, Dodd Z, Guyton M, et al. Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. Int J Drug Policy. 2017;47:202-208.
Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3(3):153-161.
Busschots D, Bielen R, Koc ÖM, et al. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era. BMC Public Health. 2021;21(1):1574.
Gane E, de Ledinghen V, Dylla DE, et al. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in phase 2 and 3 clinical trials. J Viral Hepat. 2021;28(11):1635-1642.
Aas CF, Vold JH, Skurtveit S, et al. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Subst Abuse Treat Prev Policy. 2020;15(1):44.
Akiyama MJ, Lipsey D, Heo M, et al. Low hepatitis C reinfection following direct-acting antiviral therapy among people who inject drugs on opioid agonist therapy. Clin Infect Dis. 2019;70(12):2695-2702.
Health Canada. Safer Supply Ottawa, ON 2021. Available from: https://www.canada.ca/en/health-canada/services/opioids/responding-canada-opioid-crisis/safer-supply.html
Oviedo-Joekes E, Guh D, Brissette S, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA Psychiatry. 2016;73(5):447-455.
Oviedo-Joekes E, Palis H, Guh D, et al. Treatment with injectable hydromorphone: comparing retention in double blind and open label treatment periods. J Subst Abus Treat. 2019;101:50-54.
Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev. 2011;(12):CD003410.
Eibl JK, Morin K, Leinonen E, Marsh DC. The state of opioid agonist therapy in Canada 20 years after federal oversight. Can J Psychiatr. 2017;62(7):444-450.
Talal AH, Andrews P, Mcleod A, et al. Integrated, co-located, telemedicine-based treatment approaches for hepatitis C virus management in opioid use disorder patients on methadone. Clin Infect Dis. 2018;69(2):323-331.
Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. Lancet Infect Dis. 2018;18(2):215-224.
Feld JJ, Klein MB, Rahal Y, et al. Timing of elimination of hepatitis C virus in Canada's provinces. Can Liver J. 2022;5(4):493-506.